International Journal of Radiation Oncology Biology Physics

Aims & Scope

International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.

This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation.

In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging.

Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	6.5
2024	6.40

SJR (SCImago Journal Rank)

Year	Value
2024	2.058

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	286

Journal Rank

Year	Value
2024	1361

Journal Citation Indicator

Year	Value
2024	5891

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology, Medicine and Physics and Astronomy, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)

  Citation: 3738

  Authors: James D., JoAnn, Thomas F.

• Tolerance of normal tissue to therapeutic irradiation

  Citation: 3563

  Authors: B., J., A., L., M., J.E., B., L.J., M.

• Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference

  Citation: 2289

  Authors: Mack, Gerald, Howard, Paul, William U., Gerald H., Howard

• Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials

  Citation: 2078

  Authors: Laurie, Charles, Marvin, Sucha, Theodore, Todd, W.Gillies, Roger

• Thermal dose determination in cancer therapy

  Citation: 2002

  Authors: Stephen A., William C.

• Use of Normal Tissue Complication Probability Models in the Clinic

  Citation: 1391

  Authors: Lawrence B., Ellen D., Andrew, Randall K., Louis S., Avraham, Søren M., Jiho, Joseph O.

• Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05

  Citation: 1333

  Authors: Edward, Charles, Luis, Robert, Robert, Jay, Nancy

• The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy

  Citation: 1226

  Authors: Marcel, Peter, Coen, Joos V.

• Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

  Citation: 1130

  Authors: Sandra, Bruce, Mary Louise, James S, Noriko, Leonard, Silvia C

• Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

  Citation: 1125

  Authors: Alan, Gunar K, George, John A, J.Jack, Eugene, Andrew C, Deborah A, Isaac

---